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Background and purpose: Current oral mucositis normal tissue complication probability models, based on
the dose distribution to the oral cavity volume, have suboptimal predictive power. Improving the delin-
eation of the oral mucosa is likely to improve these models, but is resource intensive. We developed and
evaluated fully-automated atlas-based segmentation (ABS) of a novel delineation technique for the oral
mucosal surfaces.
Material and methods: An atlas of mucosal surface contours (MSC) consisting of 46 patients was devel-
oped. It was applied to an independent test cohort of 10 patients for whom manual segmentation of
MSC structures, by three different clinicians, and conventional outlining of oral cavity contours (OCC),
by an additional clinician, were also performed. Geometric comparisons were made using the dice
similarity coefficient (DSC), validation index (VI) and Hausdorff distance (HD). Dosimetric comparisons
were carried out using dose-volume histograms.
Results: The median difference, in the DSC and HD, between automated-manual comparisons and
manual-manual comparisons were small and non-significant (0.024; p = 0.33 and 0.5; p = 0.88,
respectively). The median VI was 0.086. The maximum normalised volume difference between auto-
mated and manual MSC structures across all of the dose levels, averaged over the test cohort, was 8%.
This difference reached approximately 28% when comparing automated MSC and OCC structures.
Conclusions: Fully-automated ABS of MSC is suitable for use in radiotherapy dose–response modelling.
 2016 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 119 (2016) 166–171
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Oral mucositis is a common and important toxicity of head and
neck radiotherapy. It impacts on patients’ quality of life [1], poten-
tially causing pain, dysphagia [2–4] and consequential ‘‘late”
effects [5–8]. It is frequently the limiting toxicity in dose–escala-
tion and accelerated fractionation regimens that aim to improve
tumour control [9–11]. Currently, normal tissue complication
probability models have limited predictive performance and are
not routinely used to aid clinical decision-making. Additionally,
further evidence is required to find an optimal strategy for dose–
sparing of the oral mucosa to reduce the incidence of severe
toxicity.In an attempt to improve the performance of oral mucositis nor-
mal tissue complication probability (NTCP) models developed by
our group [12], we devised a novel contouring approach, which
characterises the dose delivered to the mucosal surfaces of the oral
cavity (MSC), including the buccal mucosa, mucosa of the lips and
mucosa of the oral tongue [13]. We believe that this offers an
improvement over the previously used oral cavity contours (OCC)
volume (equivalent to the ‘‘extended oral cavity” structure in inter-
national consensus guidelines detailed in [14]), which predomi-
nantly describes the dose distribution to the musculature of the
tongue and floor of mouth and does not incorporate the dose deliv-
ered to the buccal mucosa or mucosa of the lips. Differences in
delineation guidelines have been shown to lead to differences in
reported dose metrics and corresponding NTCP estimates [15]. To
test whether our novel contouring approach improves NTCP mod-
elling of oral mucositis, we must apply it to a large cohort of
patients for whom we have mucositis outcome data.
J.A. Dean et al. / Radiotherapy and Oncology 119 (2016) 166–171 167Organ-at-risk (OAR) segmentation is highly time- and resource-
intensive. This has motivated the development and evaluation of
algorithms for automatic OAR segmentation [16,17]. The burden
of OAR contouring can limit the feasibility of performing dose–
response studies that make use of a large enough patient cohort
(of the order of hundreds or thousands of patients) to enable strong
statistical inference. This is especially true when the OAR of inter-
est is not contoured as part of routine clinical practice and is chal-
lenging to delineate. This is certainly the case for MSC due to the
relatively poor image contrast on planning CT scans and its com-
plex shape. Being able to automate the MSC segmentation process
would thus be of great benefit to oral mucositis dose–response
modelling. It could also be valuable for use in treatment plan opti-
misation and assessment.
The aim of this study was to assess the performance of fully-
automated (with no post hoc editing) atlas-based segmentation
(ABS) of the MSC, in terms of geometry and dosimetry, in order
to ascertain its suitability for use in dose–response modelling.
The primary endpoint of our study was defined, prior to commenc-
ing the work, by pre hoc acceptability criteria, as follows: (i) if the
geometric differences between the ABS-generated MSC (MSCABS)
and manually delineated MSC (MSCmanual) did not exceed the
inter-clinician variability and (ii) if the dosimetric differences
between MSCABS and MSCmanual were smaller than those between
the MSCABS and OCC (which is the current international standard)
structures, then the MSCABS approach would be deemed suitable
for dose–response modelling.Materials and methods
Atlas construction
An MSC atlas of 46 patients, treated in the phase III trial of
parotid-sparing intensity-modulated versus conventional radio-
therapy in head and neck cancer (PARSPORT) (CRUK/03/005)
[18], was generated from MSCmanual structures delineated on
contrast-enhanced computed tomography (CT) scans by six clinical
oncologists (L.W., E.D., R.I., P.P., I.Ph. and J.S.) using the RayStation,
research version 4.6.100.12 treatment planning system (RaySearch
Laboratories AB, Stockholm, Sweden). We have previously
described the structure and contouring technique in detail [13].
Briefly, it includes the ‘‘buccal mucosa, buccal gingiva, gingiva
proper, lingual gingiva, lingual frenulum, alveolar mucosa, labial
mucosa, labial gingiva, labial frenulum, mucosal surface of the floor
of mouth, mucosal surface of the tongue anterior to the terminal
sulcus, and the mucosal surface of the hard palate”. As described
previously, the structures added to the atlas were the lines repre-
senting the positions of mucosal surfaces rather than the expanded
3 mm thick mucosal walls. The clinical oncologists received train-
ing in the novel contouring approach (from J.D. and L.W.) prior to
commencing the study. Once complete, the MSC structures in the
atlas were reviewed and, where necessary (7 out of 46 patients;
incorrect delineation of the surface of the tongue, likely due to
streak artefact), edited (by J.D. and C.N.). Other structures men-
tioned in this study were neither reviewed prior to the analysis
nor edited at any time.Fully-automated atlas-based segmentation
Fully-automated ABS of the MSC structure was applied to
contrast-enhanced CT scans of 10 patients (first 10 patients treated
at our institution with all data available) treated as part of the
cochlear-sparing intensity-modulated radiotherapy versus con-
ventional radiotherapy in patients with parotid tumours (COSTAR)
phase III trial (CRUK/08/004). An isotropic 1.5 mm expansion fromthe ABS contours was performed to form a 3 mm thick wall
structure, as previously described [13].Manual segmentation by multiple clinicians
MSCmanual contouring was performed for the same 10 patients
by each of three clinical oncologists (A.A., A.P. and I.Pe.). When
performing the contouring, the clinicians were blinded to the
MSCmanual structures contoured by the other clinicians and
the MSCABS structures. The contoured mucosal surface lines were
expanded to a 3 mm thick wall as previously described [13]. The
clinical oncologists received training in the contouring technique
prior to commencing the study. Manual OCC segmentation was
performed for the same 10 patients by a clinical oncologist
(K.W.) to enable dosimetric comparison between the new MSCABS
structure and the conventionally used OCC structure. The OCC
structure is based on international consensus guidelines and is
equivalent to the ‘‘extended oral cavity” OAR described in [14].Comparison of automated and manual segmentation
In-house software was written to extract the structure coordi-
nates from RayStation and perform comparisons of the different
structures using the Python programming language version 2.7.9
[19] and the NumPy version 1.9.2 [20], SciPy version 0.16.0 [21],
MatPlotLib version 1.4.3 [22] and PyDicom version 0.9.9 [23]
modules.
A geometric comparison was performed using the dice similar-
ity coefficient (DSC) [24], validation index (VI) [15] and Hausdorff
distance (HD) [25]. The DSC describes the amount of agreement
between two volumes, V and S, and is given by
DSC ¼ 2 jV \ SjjV j þ jSj ð1Þ
The VI is a recently designed measure, for geometric compar-
ison of automated and multiple manually contoured structures,
that attempts to account for uncertainties in the manual contour-
ing [26].
VI ¼
XN
k¼1
kajVkjPN
j¼1j
ajVjj
 !
k
N
 
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 
ð2Þ
where Vk is the volume of overlap between k experts out of a total of
N experts, S is the whole automated segmentation and a is a control
parameter (allowing for the weighting term (first bracket in Eq. (2))
to be changed to meet specific radiotherapy treatment planning
requirements in terms of how conservative the segmentation
should be), which was set to 1. When a = 1 the first bracket in Eq.
(2) represents the normalised frequency at which the different pro-
portions of agreeing clinicians for a volume (second bracket in Eq.
(2)) occur. VI is 0 if the ABS has no overlap with the manual struc-
tures and 1 if the ABS and all manual structures perfectly overlap.
The HD describes the maximum of all of the distances from each
point in one structure to the closest point in the other structure.
The means of the DSC and HD values for the pairwise compar-
ison between MSCABS and each of the three MSCmanual structures
(DSCpw,ABS and HDpw,ABS) were calculated for each patient. The
means of the DSC and HD values for the pairwise comparisons
between the different manually contoured structures (DSCpw,man
and HDpw,man) were also calculated for each patient and these
value subtracted from the DSCpw,ABS and HDpw,ABS values for
comparison (DSCpw,diff and HDpw,diff). A two-tailed Wilcoxon
signed-rank test was used to test for statistical significance.
A dosimetric comparison was carried out using fractional dose–
volume histograms (DVHs). The differences in the normalised
volumes receiving each dose level between the MSCABS and each
168 Automated oral mucosal surfaces segmentationof the OCC and MSCmanual structures were measured and
compared.
Results
In all cases the ABS was able to segment the MSC without any
gross errors. Fig. 1 shows an example of the ABS and manualFig. 1. Example (patient 4) of the fully-automated ABS-generated MSC structure (top
different manually delineated MSC structures (bottom; pink, purple and coral). For eac
coronal, sagittal and axial views, respectively.
Table 1
Geometric comparison of the automated and manual MSC contours.
Patient VI DSCpw,ABS DSCpw,man DSCpw,dif
1 0.033 0.070 0.134 0.064
2 0.025 0.062 0.269 0.207
3 0.089 0.210 0.159 0.052
4 0.152 0.327 0.349 0.022
5 0.115 0.270 0.352 0.082
6 0.124 0.283 0.309 0.026
7 0.063 0.162 0.111 0.051
8 0.056 0.137 0.098 0.040
9 0.105 0.243 0.272 0.029
10 0.082 0.185 0.204 0.018
Median 0.086 0.198 0.236 0.024
(p⁄ = 0.33
VI = validation index; DSCpw,ABS = mean of the dice similarity coefficients for pairwise c
manually delineated structures; DSCpw,man = mean of the dice similarity coefficients for p
different combinations of pairwise comparisons); DSCpw,diff = DSCpw,ABS minus DSCpw,man
automatically segmented structure and each of the three manually delineated structures
three different manually delineated structures (3 different combinations of pairwise co
signed-rank test.MSC contours for patient 4. The greatest variation between the
structures is in the position of the posterior border, the lateral
extents of the buccal mucosa and the inferior extent of the mucosa
where the lateral tongue base meets the mucosa overlying the floor
of mouth. This was representative of the whole 10-patient cohort.
The ABS performed poorest, as assessed by DSC, HD and VI, for
patient 2. In this case the MSCABS structure extended too farand bottom; green), the manually delineated OCC structure (top; red) and three
h set of 3 images (top and bottom) the left, top right and bottom right images are
f HDpw,ABS (mm) HDpw,man (mm) HDpw,diff (mm)
21.0 16.1 4.9
21.3 14.8 6.5
13.3 14.4 1.1
13.7 13.6 0.1
11.5 15.4 3.9
13.1 16.1 3.0
12.5 17.2 4.7
17.8 21.0 3.2
17.4 14.8 2.6
16.7 13.4 3.3
2)
15.2 15.1 0.5
(p⁄ = 0.881)
omparisons between the automatically segmented structure and each of the three
airwise comparisons between the three different manually delineated structures (3
; HDpw,ABS = mean of the Hausdorff distances for pairwise comparisons between the
; HDpw,man = mean of the Hausdorff distances for pairwise comparisons between the
mparisons); HDpw,diff = HDpw,ABS minus HDpw,man; *p-value for two-tailed Wilcoxon
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of mouth.
The geometric comparisons are described in Table 1. The DSC
increases with increasing overlap between structures. The HD
decreases with increasing proximity of structures. The median val-
ues of DSCpw,diff and HDpw,diff were small in magnitude and not
close to statistically significant at the p = 0.05 level. This indicates
that the geometric differences between the MSCABS and MSCmanual
structures did not exceed the geometric differences between
MSCmanual structures delineated by different clinicians. Therefore,
our pre hoc criterion (i) was met. The VI values were substantially
lower than the DSCpw,ABS values. This is because DSCpw,ABS gener-
ally overestimates the agreement between ABS and manual struc-
tures due to not incorporating the amount of agreement between
multiple clinician-delineated structures.
Fig. 2 summarises the DVHs for the 10-patient cohort using the
different structures. Fig. 3 shows the pairwise differences in theFig. 2. Fractional dose–volume histograms. Black lines show group medians and
grey lines show group ranges. OCC_KW = oral cavity contours (by K.W.);
MSC_AA = manual mucosal surface contours (by A.A.); MSC_AP = manual mucosal
surface contours (by A.P.); MSC_IPe = manual mucosal surface contours (by I.Pe.);
MSC_Atlas = atlas-based segmentation mucosal surface contours.
Fig. 3. Normalised volume differences, at each dose level, between atlas-based segmenta
manually delineated mucosal surface contours. Black lines show medians and grey lin
MSC_AA = manual mucosal surface contours (by A.A.); MSC_AP = manual mucosal su
MSC_Atlas = atlas-based segmentation mucosal surface contours.DVHs between the different structures for each of the 10 patients.
The median MSCABS DVH falls within the centre of the median
MSCmanual DVH range across the three clinicians (A.A., A.P., I.Pe.).
The maximum normalised volume differences at any dose level
were, on average across the cohort, within 8%. The dose distribu-
tions extracted using the OCC structure characterise larger vol-
umes receiving low and intermediate doses than any of the
automated or manual MSC structures. The maximum normalised
volume difference between the MSCABS and OCC structures, aver-
age across the cohort, was 28%. This indicates that the dosimetric
differences between the MSCABS and MSCmanual structures were
small and substantially smaller than the differences between the
MSCABS and OCC structures. Therefore, our pre hoc criterion (ii)
and, hence, the primary endpoint of our study was met. Moreover,
the MSCABS (and MSCmanual) structures capture information on the
dose delivered to the buccal mucosa, which is not captured by the
OCC structure (Fig. 1).Discussion
The results of the geometric comparison between the MSCABS
and MSCmanual structures indicate that the difference between
fully-automated and manual segmentation of the MSC structure
is within the inter-clinician variability of the manual delineation.
The same is true of the dosimetric comparison between the MSCABS
and MSCmanual structures. Furthermore, the dosimetric comparison
demonstrates that the DVHs for the MSCABS structure are more
similar to the ‘‘gold standard” MSCmanual structures than the OCC
structure that was previously employed for dose–response mod-
elling. Based on our pre hoc criteria, the primary endpoint of our
study was met. We, therefore, suggest that the MSCABS structure
is suitable for use for oral mucosa dose–response modelling.
The DSC and VI values are low for the comparison of the MSCABS
and MSCmanual structures and the inter-clinician comparisons. This
is a result of the nature of the morphology of the structure being
wall-like. DSC is highly sensitive to the volume of the structure.
The same is also true of the VI metric. This can be illustrated using
a ‘‘toy” example. Two cubes, of dimension 10 units, diagonally dis-
placed, by 1 unit in each dimension, have a DSC of 0.729. Two hol-
low cubes, of dimension 10 units and thickness 1 unit, with the
same displacement, have a substantially lower DSC of 0.098. Thistion mucosal surface contours and oral cavity contours and each of the three sets of
es show the individual patients values. OCC_KW = oral cavity contours (by K.W.);
rface contours (by A.P.); MSC_IPe = manual mucosal surface contours (by I.Pe.);
170 Automated oral mucosal surfaces segmentationmakes it challenging to determine whether an automated contour-
ing approach is suitable for clinical use solely using a threshold
value of the DSC or VI. The current ‘‘gold-standard” for OAR con-
touring is manual delineation by a trained expert [27]. However,
variability exists between delineations performed by different
experts, even when following the same guidelines [28]. Therefore,
there exists a rationale for deciding whether an automated
approach is fit for clinical use based on whether or not it falls
within or outside the variability of clinical oncologists who would
perform the manual delineation for clinical use. Several studies
evaluating the performance of automated structure segmentation
simply use the DSC magnitude value to assess suitability for clini-
cal use. We suggest that our method, in which we compared the
differences in automated and manually segmented structures to
inter-clinician variability in the manual segmentation, is, at least,
equally valid.
The median HDpw,diff value provides further indication that the
automated segmentation fell within the range of the inter-clinician
variability in manual segmentation. Unlike the DSC and VI values,
the HD values are not sensitive to the volumes of the structures.
Using the same ‘‘toy” example, the two displaced cubes have a
HD of 1.73 units and the two displaced hollow cubes also have a
HD of 1.73 units. This suggests that HD is a more suitable metric
for assessing the similarity between structure segmentations than
DSC for small volume or wall-like structures.
The dosimetric comparison data (Figs. 2 and 3) indicate that the
MSCABS structure provides a dose distribution to the oral mucosal
surfaces that is closer to the MSCmanual structures than the previ-
ously used OCC structure. This provides further rationale for using
the MSCABS structure, rather than the OCC structure, for dose–
response modelling. Many other studies evaluating the performance
of automated structure segmentation consider only geometric
indices and do not directly measure the effects of geometric differ-
ences on the dose distribution to the segmented structure. We sug-
gest that dosimetric comparisons can also provide useful, and often
more relevant, information in performing such evaluations, partic-
ularly for small or wall-like structures.
A potential limitation of our study is the use of six different clin-
icians to perform the delineation of the structures included in the
atlas. This may have led to increased variability in the atlas MSC
structures compared with what might have been produced had a
single clinician performed all of the delineations. The fact that
the VI values were substantially lower than the DSCpw,ABS values
indicates that there was uncertainty in the manual delineation of
the MSC structure. This is likely due to the relatively poor CT image
contrast and complex shape of the structure. We trained the clini-
cians performing the delineation and independently reviewed and
edited the contours in an attempt to minimise the effects of inter-
clinician variability in the atlas. However, some variation inevita-
bly remained. This could explain the poorer performance of the
ABS for patient 2. The MSC for the atlas patient selected in the ini-
tial rigid registration comparison step of the ABS may also have
extended too far inferiorly. Multi-atlas-based segmentation (using
information from all of the available patients, rather than just the
one that is the closest match, to perform the automated segmenta-
tion) might improve the robustness of the automated segmenta-
tion (at the expense of computational time) [29], but we were
unable to assess this, as RayStation does not currently include a
multi-atlas segmentation algorithm. We would expect this
approach to reduce the sensitivity of the ABS to the atlas patient
selected and, therefore, improve the ABS performance for patient 2.
Moreover, it should be noted that the patients included in this
study did not have tumours of the oral cavity. Therefore, based
on our data, we cannot guarantee that the performance of the auto-
mated or manual segmentation of the MSC for patients with oral
cavity tumours will match that reported in this study. The cohortthat we intend to apply this technique to for NTCP modelling does
not contain patients with oral cavity tumours. Including patients
for whom the MSC include tumour could confound investigations
of the dose–response relationship of normal oral mucosa. Further-
more, it is unlikely that the MSC could be spared if it overlapped
with the planning target volume, reducing the utility of segment-
ing the MSC.
When applying the MSC structure to NTCP modelling, it is
important to consider that scoring of oral mucositis also takes into
account mucosal surfaces not included as part of the MSC struc-
ture, particularly the oropharynx. For this reason, when applying
the MSC approach to NTCP modelling of oral mucositis, we recom-
mend that the pharyngeal mucosa also be considered as an OAR.
In conclusion, we performed a thorough geometric and dosi-
metric assessment of fully-automated ABS of the novel MSC OAR
structure and demonstrated that it is suitable for use in radiother-
apy dose–response studies. This represents the first evaluation of a
method to fully segment the oral mucosal surfaces automatically.
In the future, we aim to apply this contouring approach to a cohort
of patients from six head and neck radiotherapy trials and establish
whether it improves the predictive performance of NTCP modelling
of severe acute mucositis.Conflict of interest statement
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